GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on January 14, 2025, serves as a transaction notification for GSK Plc, a foreign private issuer. The filing discloses share transactions conducted by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them during the month of January 2025. The transactions occurred on the London Stock Exchange (XLON) involving Ordinary Shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
Key Financial Metrics and Transaction Details
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively details specific share acquisitions by senior executives. Two distinct types of transactions were reported:
- Share Reward Plan Acquisitions: Executed on January 10, 2025, at a price of £13.4894 per share. These involved "partnership shares" and "matching shares."
- Dividend Re-investment: Executed on January 9, 2025, at a price of £13.5899 per share. These acquisitions resulted from the re-investment of dividends paid on January 9, 2025.
| Executive Name | Position | Transaction Date | Transaction Type | Price (£) | Total Volume |
|---|---|---|---|---|---|
| Emma Walmsley | CEO | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| Julie Brown | CFO | 2025-01-10 | Share Reward Plan | 13.4894 | 20 |
| James Ford | SVP, General Counsel | 2025-01-10 | Share Reward Plan | 13.4894 | 20 |
| Sally Jackson | SVP, Global Communications | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| David Redfern | President, Corporate Development | 2025-01-10 | Share Reward Plan | 13.4894 | 20 |
| Regis Simard | President, Global Supply Chain | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| Philip Thomson | President, Global Affairs | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| Deborah Waterhouse | CEO, ViiV Healthcare | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| Victoria Whyte | Company Secretary | 2025-01-10 | Share Reward Plan | 13.4894 | 18 |
| Emma Walmsley | CEO | 2025-01-09 | Dividend Re-investment | 13.5899 | 30 |
| Diana Conrad | Chief People Officer | 2025-01-09 | Dividend Re-investment | 13.5899 | 5 |
| James Ford | SVP, General Counsel | 2025-01-09 | Dividend Re-investment | 13.5899 | 10 |
| Sally Jackson | SVP, Global Communications | 2025-01-09 | Dividend Re-investment | 13.5899 | 20 |
| Luke Miels | Chief Commercial Officer | 2025-01-09 | Dividend Re-investment | 13.5899 | 4 |
| David Redfern | President, Corporate Development | 2025-01-09 | Dividend Re-investment | 13.5899 | 82 |
| Regis Simard | President, Global Supply Chain | 2025-01-09 | Dividend Re-investment | 13.5899 | 31 |
| Philip Thomson | President, Global Affairs | 2025-01-09 | Dividend Re-investment | 13.5899 | 51 |
| Deborah Waterhouse | CEO, ViiV Healthcare | 2025-01-09 | Dividend Re-investment | 13.5899 | 67 |
| Victoria Whyte | Company Secretary | 2025-01-09 | Dividend Re-investment | 13.5899 | 62 |
Material Changes and Outlook
The filing text does not provide information regarding material changes in business operations, revenue, or profit compared to prior periods. It contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document is strictly a regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Dividend Payment Date: Verify the dividend payment date of January 9, 2025, to confirm the timing of the re-investment transactions.
- Share Price Consistency: Note the slight price difference between the Share Reward Plan acquisitions (£13.4894) and the Dividend Re-investment acquisitions (£13.5899) occurring on consecutive days.
- Executive Participation: Confirm that all listed senior executives participated in the Share Reward Plan, indicating broad alignment with company equity incentives.
- Transaction Volume: The volumes are nominal (ranging from 4 to 82 shares per transaction), typical for dividend re-investment plans and standard executive matching schemes.